These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 1561416

  • 1. Differentiation of residual or recurrent tumors from post-treatment changes with F-18 FDG PET.
    Kim EE, Chung SK, Haynie TP, Kim CG, Cho BJ, Podoloff DA, Tilbury RS, Yang DJ, Yung WK, Moser RP.
    Radiographics; 1992 Mar; 12(2):269-79. PubMed ID: 1561416
    [Abstract] [Full Text] [Related]

  • 2. Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.
    Kahn D, Follett KA, Bushnell DL, Nathan MA, Piper JG, Madsen M, Kirchner PT.
    AJR Am J Roentgenol; 1994 Dec; 163(6):1459-65. PubMed ID: 7992747
    [Abstract] [Full Text] [Related]

  • 3. Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).
    Duhaylongsod FG, Lowe VJ, Patz EF, Vaughn AL, Coleman RE, Wolfe WG.
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):130-9; discussion 139-40. PubMed ID: 7609536
    [Abstract] [Full Text] [Related]

  • 4. Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography.
    Glantz MJ, Hoffman JM, Coleman RE, Friedman AH, Hanson MW, Burger PC, Herndon JE, Meisler WJ, Schold SC.
    Ann Neurol; 1991 Apr; 29(4):347-55. PubMed ID: 1929205
    [Abstract] [Full Text] [Related]

  • 5. Detecting recurrent or residual lung cancer with FDG-PET.
    Inoue T, Kim EE, Komaki R, Wong FC, Bassa P, Wong WH, Yang DJ, Endo K, Podoloff DA.
    J Nucl Med; 1995 May; 36(5):788-93. PubMed ID: 7738649
    [Abstract] [Full Text] [Related]

  • 6. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine PET in detection of malignant tumors.
    Inoue T, Kim EE, Wong FC, Yang DJ, Bassa P, Wong WH, Korkmaz M, Tansey W, Hicks K, Podoloff DA.
    J Nucl Med; 1996 Sep; 37(9):1472-6. PubMed ID: 8790196
    [Abstract] [Full Text] [Related]

  • 7. Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose.
    Patz EF, Lowe VJ, Hoffman JM, Paine SS, Harris LK, Goodman PC.
    Radiology; 1994 May; 191(2):379-82. PubMed ID: 8153309
    [Abstract] [Full Text] [Related]

  • 8. Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET.
    Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM.
    Radiology; 1995 Apr; 195(1):47-52. PubMed ID: 7892494
    [Abstract] [Full Text] [Related]

  • 9. Characterization of chest masses by FDG positron emission tomography.
    Hübner KF, Buonocore E, Singh SK, Gould HR, Cotten DW.
    Clin Nucl Med; 1995 Apr; 20(4):293-8. PubMed ID: 7788982
    [Abstract] [Full Text] [Related]

  • 10. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.
    Janus TJ, Kim EE, Tilbury R, Bruner JM, Yung WK.
    Ann Neurol; 1993 May; 33(5):540-8. PubMed ID: 8498831
    [Abstract] [Full Text] [Related]

  • 11. PET versus SPECT in distinguishing radiation necrosis from tumor recurrence in the brain.
    Buchpiguel CA, Alavi JB, Alavi A, Kenyon LC.
    J Nucl Med; 1995 Jan; 36(1):159-64. PubMed ID: 7799071
    [Abstract] [Full Text] [Related]

  • 12. Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain.
    Patronas NJ, Di Chiro G, Brooks RA, DeLaPaz RL, Kornblith PL, Smith BH, Rizzoli HV, Kessler RM, Manning RG, Channing M, Wolf AP, O'Connor CM.
    Radiology; 1982 Sep; 144(4):885-9. PubMed ID: 6981123
    [Abstract] [Full Text] [Related]

  • 13. Fluorodeoxyglucose PET of abdominal and pelvic neoplasms: potential role in oncologic imaging.
    Goldberg MA, Lee MJ, Fischman AJ, Mueller PR, Alpert NM, Thrall JH.
    Radiographics; 1993 Sep; 13(5):1047-62. PubMed ID: 8210589
    [Abstract] [Full Text] [Related]

  • 14. Where can FDG-PET contribute most to anatomical imaging problems?
    Bingham JB.
    Br J Radiol; 2002 Nov; 75 Spec No():S39-52. PubMed ID: 12519735
    [No Abstract] [Full Text] [Related]

  • 15. Impact of fluorodeoxyglucose positron emission tomography on the clinical management of patients with glioma.
    Deshmukh A, Scott JA, Palmer EL, Hochberg FH, Gruber M, Fischman AJ.
    Clin Nucl Med; 1996 Sep; 21(9):720-5. PubMed ID: 8879874
    [Abstract] [Full Text] [Related]

  • 16. Local recurrence of rectal cancer: evaluation with F-18 fluorodeoxyglucose PET imaging.
    Keogan MT, Lowe VJ, Baker ME, McDermott VG, Lyerly HK, Coleman RE.
    Abdom Imaging; 1997 Sep; 22(3):332-7. PubMed ID: 9107663
    [Abstract] [Full Text] [Related]

  • 17. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.
    Weber W, Bartenstein P, Gross MW, Kinzel D, Daschner H, Feldmann HJ, Reidel G, Ziegler SI, Lumenta C, Molls M, Schwaiger M.
    J Nucl Med; 1997 May; 38(5):802-8. PubMed ID: 9170450
    [Abstract] [Full Text] [Related]

  • 18. PET-FDG of pleomorphic xanthoastrocytoma.
    Bicik I, Raman R, Knightly JJ, Di Chiro G, Fulham MJ.
    J Nucl Med; 1995 Jan; 36(1):97-9. PubMed ID: 7799091
    [Abstract] [Full Text] [Related]

  • 19. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome.
    Valk PE, Budinger TF, Levin VA, Silver P, Gutin PH, Doyle WK.
    J Neurosurg; 1988 Dec; 69(6):830-8. PubMed ID: 2848111
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.